Compare AWX & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AWX | PHIO |
|---|---|---|
| Founded | 1998 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3M | 12.5M |
| IPO Year | 1998 | 2011 |
| Metric | AWX | PHIO |
|---|---|---|
| Price | $2.55 | $1.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.67 |
| AVG Volume (30 Days) | 2.3K | ★ 2.4M |
| Earning Date | 01-01-0001 | 06-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $53,090,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.14 | N/A |
| 52 Week Low | $2.10 | $0.81 |
| 52 Week High | $5.43 | $4.19 |
| Indicator | AWX | PHIO |
|---|---|---|
| Relative Strength Index (RSI) | 43.16 | 57.78 |
| Support Level | $2.47 | $1.01 |
| Resistance Level | $2.62 | $1.43 |
| Average True Range (ATR) | 0.05 | 0.08 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 8.70 | 95.19 |
Avalon Holdings Corp is a waste management company. The company provides waste management services to industrial, commercial, municipal, and governmental customers in selected northeastern and midwestern U.S. markets. The company has two operating segments. The Waste management services segment which is the key revenue driver, includes waste disposal services, captive landfill operations, and saltwater injection well operations. Its Golf and related operations segment includes management of golf courses and related clubhouses, a hotel, fitness centers, tennis courts, salon and spa services, dining, banquet, and conference facilities.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.